Entering text into the input field will update the search result below

Top 10 sectors that are the most expensive to borrow and short

May 13, 2011 9:41 AM ETAVNR, TOVX, SKBI, LSTA, RPRX-OLD, ALBO, AXN, SNOA, MNK
shortside profile picture
shortside's Blog
40 Followers
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Seeking Alpha Analyst Since 2010

Astec Analytics, a division of SunGard Data Systems, provides investors with short selling market color using data from the securities lending market.

As of May 12, Life Sciences was the most expensive sector to borrow and short.  On average, the cost to short stocks in the sector was 1,595 basis points annualized.  The most expensive stocks in the sector are APRICUS BIOSCIENCES INC (APRI), RADIENT PHARMACEUTICALS CORP (RPC), PURE BIOSCIENCE INC  (OTC:PURE), BIOANALYTICAL SYS INC  (BASI), ARROWHEAD RESH CORP  (ARWR), ACCELR8 TECHNOLOGY CORP  (AXK), GENETIC TECHNOLOGIES LTD  (GENE), BG MEDICINE INC  (OTC:BGMD), COMPUGEN LTD  (CGEN), and BIODELIVERY SCIENCES INTL IN (BDSI).

The most expensive stocks to borrow and short in the Pharmaceutical sector are SOMAXON PHARMACEUTICALS INC (SOMX), AVANIR PHARMACEUTICALS INC  (AVNR), ADEONA PHARMACEUTICALS INC  (AEN), SKYSTAR BIO-PHARMA CO  (OTC:SKBI), NEOSTEM INC  (NBS), REPROS THERAPEUTICS INC  (RPRX),
BIODEL INC  (BIOD), AOXING PHARMACEUTICAL CO INC (AXN), OCULUS INNOVATIVE SCIENCES I (OCLS), and CADENCE PHARMACEUTICALS INC  (CADX).



Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.